SHPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Shuttle Pharmaceuticals Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 24, 2026
$4.72−0.36 (-7.09%)
Close on Oct 19, 2026
- Market cap
- $4.79M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
2.2%
0M of 5M shares
Institutional holders
5
5 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
6 buys · 5 sales
Net sold $323.07K
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SHPH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 78,597 | 1.65% | $255 | New | 0.00% |
| Citadel Advisors LLC | 24,354 | 0.51% | $79.15K | New | 0.00% |
| Barclays PLC | 750 | 0.02% | $2.44K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 389 | 0.01% | $1.26K | New | 0.00% |
| Wall Street Access Asset Management, LLC | 120 | 0.00% | $390 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 5 | 0M | 2.2% | 5 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SHPH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Blackstone Alternative Multi-Strategy Fund | -100 | -0.00% | -$325 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ryan Trasolini | Co-Chief Executive Officer | – | – | Jun 1, 2026 |
| Yuying Liang | Chief Financial Officer | – | – | Jan 12, 2026 |
| Timothy J. Lorber | Chief Financial Officer | 227,635 | 4.78% | Aug 12, 2025 |
| Chris Cooper | Interim Co-CEO | – | – | Apr 2, 2025 |
| Angel Liriano | Director | 0 | – | Oct 29, 2025 |
| Arachchige Sachin Eranga Pathigoda | Director | 0 | – | Oct 28, 2025 |
| Adam V. Chambers | Director | 0 | – | Sep 8, 2025 |
| Steven M. Richards | Director | 210,004 | 4.41% | Aug 13, 2025 |
| Joseph Tung | Director | 184,162 | 3.87% | Aug 12, 2025 |
| George Scorsis | Director | 184,162 | 3.87% | Aug 12, 2025 |
| Oleh Nabyt | Director | 184,162 | 3.87% | Aug 12, 2025 |
| Joshua Schafer | Director | 210,004 | 4.41% | Feb 6, 2025 |
| Milton Brown | Director | 346,617 | 7.27% | Feb 5, 2025 |
| Financial Lp Hrt | 10% owner | 0 | – | Jul 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Financial Lp Hrt 10% owner | Jul 14, 2026 | Sale | −82,116 | $4.48 | $367.88K | 0 |
| Financial Lp Hrt 10% owner | Jul 13, 2026 | Sale | −1,033 | $4.67 | $4.82K | 60,238 |
| Financial Lp Hrt 10% owner | Jul 10, 2026 | Buy | +731 | $3.11 | $2.27K | 61,271 |
| Financial Lp Hrt 10% owner | Jul 9, 2026 | Buy | +8,266 | $3.38 | $27.94K | 60,540 |
| Financial Lp Hrt 10% owner | Jul 8, 2026 | Sale | −18,531 | $3.52 | $65.23K | 52,274 |
| Financial Lp Hrt 10% owner | Jul 7, 2026 | Sale | −10,580 | $3.33 | $35.23K | 70,805 |
| Financial Lp Hrt 10% owner | Jul 6, 2026 | Sale | −9,022 | $3.51 | $31.67K | 81,385 |
| Financial Lp Hrt 10% owner | Jul 2, 2026 | Buy | +7,851 | $3.54 | $27.79K | 90,407 |
| Financial Lp Hrt 10% owner | Jul 1, 2026 | Buy | +3,959 | $3.30 | $13.06K | 82,556 |
| Financial Lp Hrt 10% owner | Jun 30, 2026 | Buy | +6,755 | $3.23 | $21.82K | 78,597 |
| Financial Lp Hrt 10% owner | Jun 29, 2026 | Buy | +25,836 | $3.44 | $88.88K | 71,842 |
| Joshua Schafer Director | Dec 31, 2024 | Award | +209,790 | – | – | 210,004 |
| Steven M. Richards Director | Dec 31, 2024 | Award | +209,790 | – | – | 210,004 |
| Steven M. Richards Director | Dec 23, 2024 | Award | +209,790 | – | – | 210,004 |
| Joshua Schafer Director | Dec 23, 2024 | Award | +209,790 | – | – | 210,004 |
| Milton Brown Director | Dec 23, 2024 | Award | +209,790 | – | – | 346,617 |
| Mira Jung Chief Scientific Officer | May 1, 2024 | Award | −598 | $11.28 | $6.75K | 135,715 |
| Hoek Michael Vander Chief Financial Officer | Mar 8, 2024 | Award | +100,000 | – | – | 103,852 |
| Milton Brown Director | Dec 13, 2023 | Sale | −2,921 | $0.46 | $1.34K | 1,094,610 |
| Bette Jacobs Director | Dec 13, 2023 | Sale | −4,157 | $0.46 | $1.91K | 27,064 |
| Anatoly Dritschilo CEO and Chairman, Director, 10% owner | Aug 14, 2023 | Gift | −2,100,000 | – | – | 1,104,407 |
| Anatoly Dritschilo CEO and Chairman, Director, 10% owner | Aug 14, 2023 | Gift | +2,100,000 | – | – | 2,100,000 |
| Chris Senanayake Director | Dec 29, 2022 | Sale | −1,626 | $1.61 | $2.62K | 2,791 |
| Steven M. Richards Director | Dec 29, 2022 | Sale | −995 | $1.61 | $1.60K | 1,707 |
| William Adkins – | Dec 29, 2022 | Sale | −995 | $1.61 | $1.60K | 184,071 |
| Milton Brown Director | Dec 29, 2022 | Sale | −995 | $1.61 | $1.60K | 1,072,531 |
| Anatoly Dritschilo CEO and Chairman, Director, 10% owner | Dec 29, 2022 | Sale | −8,372 | $1.61 | $13.48K | 1,085,200 |
| Tyvin Rich Chief Medical Officer | Dec 29, 2022 | Sale | −1,414 | $1.61 | $2.28K | 2,429 |
| Bette Jacobs Director | Dec 29, 2022 | Sale | −4,366 | $1.61 | $7.03K | 31,221 |
| Mira Jung Chief Scientific Officer | Dec 29, 2022 | Sale | −328 | $1.61 | $528 | 1,071,388 |
| Hoek Michael Vander Chief Financial Officer | Dec 29, 2022 | Sale | −2,243 | $1.61 | $3.61K | 3,852 |
| Peter Dritschilo President and COO | Dec 29, 2022 | Sale | −3,820 | $1.61 | $6.15K | 6,560 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.